Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01260506 · ClinicalTrials.gov registry record · Phase 1
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
A Phase 1 study, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT01260506 is a Phase 1 study that has completed, run by Vascular Biogenics Ltd. operating as VBL Therapeutics. The registered enrollment target is 75 participants.
The verdict
NCT01260506, a Phase 1 study, has completed, sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.
Interventions
- DRUG Bevacizumab
- DRUG VB-111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2010-12 |
| Est. Completion | 2018-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01260506
The ClinicalTrials.gov registry entry for NCT01260506 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vascular Biogenics Ltd. operating as VBL Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT01260506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01260506 about?
NCT01260506 is a clinical study titled "Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme". The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.
What is the current status of trial NCT01260506?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2010-12. Estimated completion is 2018-12-20.
What interventions are being tested in trial NCT01260506?
The interventions under investigation include: Bevacizumab (DRUG), VB-111 (DRUG).
Who is sponsoring clinical trial NCT01260506?
This trial is sponsored by Vascular Biogenics Ltd. operating as VBL Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.